The Gratitude Gallery – A Positive Psychology Intervention

Overview

This study will assess the feasibility and acceptability of a positive psychology intervention, The Gratitude Gallery, for increasing gratitude in adults. The study hypothesizes that participants will find the activity feasible and acceptable and complete the intervention as directed. The project also hypothesizes that those that complete the intervention will show an increase in self-reported gratitude, as well as a decrease in symptoms of anxiety and depression.

Full Title of Study: “The Gratitude Gallery – A Positive Psychology Intervention”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2, 2021

Interventions

  • Behavioral: taking photographs
    • Participants will photograph images (using a cell phone) that invoke a feeling of gratitude. At least 1 photograph (at any time of the day) should be taken for a period of three weeks. Once the photo images are captured, the participant should spend a moment looking at the image and reflecting on why they are grateful for the subject of the photograph.

Arms, Groups and Cohorts

  • Experimental: Taking Photographs
    • Participants will be asked to take photos with their cell phone.

Clinical Trial Outcome Measures

Primary Measures

  • Acceptability of the The Gratitude Gallery
    • Time Frame: 2 years
    • Number of participants that are eligible for the study compared to the number of patients that are enrolled. The higher the ratio of participants enrolled the higher acceptability.
  • Feasibility of the The Gratitude Gallery
    • Time Frame: up to 21 days (days of treatment)
    • Participants that complete 15 of the 21 intervention days will be considered to be feasible.
  • Changes in the level of reported gratitude as measured by the Gratitude Questionnaire – 6 (GQ-6).
    • Time Frame: Baseline, up to day 60
    • This is a six question, self-reported survey designed to assess individual differences in the proneness to experience gratitude in daily life. The GQ-6 uses a 7-point Likert scale with responses that range from “strongly disagree” to “strongly agree”. Questions 3 and 6 are reverse scored. A higher total score indicated higher levels of gratitude.

Secondary Measures

  • Changes in positive and negative affect as measured by the Positive and Negative Affect Scale (PANAS) Scale
    • Time Frame: Baseline, up to day 60
    • The PANAS scale is a 20 item mood scale measuring the two primary dimensions of mood. Responses on a 5-point Likert Scale range from “very slightly or not at all” to “extremely”. Positive affect and negative affect questions are grouped and scored separately. The PANAS has been shown to be sensitive to short-term fluctuations in mood in addition to showing stability over a longer (2-month) time period.
  • Changes in General Life Satisfaction – Fixed Form B from the NIH Toolbox
    • Time Frame: Baseline, up to day 60
    • This is a brief 5-item questionnaire which can be administered to adults over the age of 18. It uses a 7-point Likert scale with responses that range from “strongly disagree” to “strongly agree”. The scores for each question are added to create a raw score. This raw score is then converted to a T-score using a conversion table which represents the mean of the United States population.
  • Changes in sleep quality using the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance – Short Form 4a
    • Time Frame: Baseline, up to day 60
    • This assessment consists of 4 items which measure sleep quality and sleep disturbances using a 5 point likert scale ranging in value from 1 to 5 with higher scores indicating greater sleep quality.
  • Changes in depressive symptoms using the Patient Health Questionnaire 9-Item (PHQ-9)
    • Time Frame: Baseline, up to day 60
    • The PHQ-9 is a brief, self-administered questionnaire that scores each of the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria for depression on a scale from 0 to 3. Response options include “not at all”, “several days”, more than half the days” and “nearly every day”. It is a validated measure of depression severity. Scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively.
  • Changes in anxiety symptoms using the Generalized Anxiety scale (GAD-7)
    • Time Frame: Baseline, up to day 60
    • The GAD-7 is a self-reported questionnaire that assesses for the seven core symptoms of generalized anxiety disorder and severity. Response options include “not at all”, “several days”, more than half the days” and “nearly every day”. GAD-7 total score for the seven items ranges from 0 to 21. Scores of 5, 10, and 15 represent cut-points for mild, moderate, and severe anxiety, respectively.

Participating in This Clinical Trial

Inclusion Criteria

  • Able to read/understand English and give consent – Owns a smart phone capable of taking pictures – Willing and able to comply with all aspects of study procedures – PHQ-9 score greater or equal to 5 but less or equal to 14 with no suicidal ideation – Generalized anxiety disorder (GAD-7) score greater or equal to 0 but less or equal to 9 – No plan to initiate a new program that could increase positive affect during the study period (e.g., psychotherapy, new exercise regimen, meditation classes) – If on medication then stable (at least 3 months) on dose or not on medication Exclusion Criteria:

  • Having a psychotic disorder active suicidality or severe depressive or anxiety symptoms – Other factors that at the discretion of the investigators that would adversely affect study participation

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Michigan
  • Provider of Information About this Clinical Study
    • Principal Investigator: Erin Hendriks, Assistant Professor of Family Medicine – University of Michigan
  • Overall Official(s)
    • Erin Hendriks, MD, Principal Investigator, University of Michigan

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.